USPs that matters:

New: Defence-ETF Themefolio

Advanced IPO-Section: Equities & ETF (link)

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Powerful & free of charge: Tools 4 WebMaster ...

Tipp: Exclusive Newswire Digest

Info-Hub

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Campus

KnowHow & Education
Advanced Event Calendar Feed
Mentoring & Coaches

Press

FAQ

What's New

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Home
Terminal
CureVac N.V.

CureVac N.V.

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

001543603

SEDOL

BN4RD42

CIK

0001809122

www.curevac.com

LEI:

New: Infographics X-Lab

CureVac is a Member of Themefolio

Covid19-STX

FIGI: BBG00W9LXXJ4

CVAC

CureVac N.V.

GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

CureVac

Click to initiate

ENTERPRISE

NAME

CureVac N.V.

ISIN

NL0015436031

TICKER

CVAC

MIC

XNAS

REUTERS

CVAC.OQ

BLOOMBERG

CVAC US

F&G: 61

6.097,32 S&P · 19,05 Vola-Index · 107.510,41 BTC · 1,16572 EURUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading

Knock out & Barriers (IG)

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Tue, 24.06.2025

CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA – June 24, 2025 – CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting. The sharehold...

Research & Analysis

Tue, 20.05.2025

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected ...

Research & Analysis

Thu, 15.05.2025

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent cla...

Research & Analysis

Thu, 10.04.2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024and Provides Business Update Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first d...

Research & Analysis

Tue, 08.04.2025

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 TÜBINGEN, Germany/BOSTON, USA – April 08, 2025 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial result...

Research & Analysis

Mon, 07.04.2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac’s investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC e...

Research & Analysis

Thu, 27.03.2025

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025...

Research & Analysis

Tue, 18.02.2025

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA techno...

Research & Analysis

Tue, 12.11.2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024and Provides Business Update Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected c...

Research & Analysis

Thu, 07.11.2024

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 TÜBINGEN, Germany/BOSTON, USA – November 7, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will r...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 30.603 Visitors - 22.181 Registered members - 13 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Congratulation Madagascar

celebrating National Holiday

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Visual Sitemap

Helpdesk

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Consumer information

Imprint

smart.AD